Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD81 | P60033 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397368 | 0.83 | CD81 (0.32) | CD81 | |
| SCHEMBL12946601 | 0.83 | APLNR (0.33) | CD81 | |
| SCHEMBL12946602 | 0.81 | PKM (0.31) | — | |
| SCHEMBL8189959 | 0.80 | — | — | |
| SCHEMBL18723756 | 0.79 | CD81 (0.32) | CD81 | |
| SCHEMBL6560389 | 0.79 | GRM2 (0.38) | CD81 | |
| SCHEMBL4905385 | 0.79 | GRM2 (0.38) | CD81 | |
| SCHEMBL16152426 | 0.79 | GRM2 (0.38) | CD81 | |
| SCHEMBL4905394 | 0.79 | GRM2 (0.38) | CD81 | |
| SCHEMBL15968423 | 0.79 | CD81 (0.32) | CD81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560598-B2 | reacting a saturated, tertiary terpene alcohol with hypochloric acid under conditions effective to produce at least one oxidation product selected from the group consisting of cyclic ethers, chloroketones, and mixtures thereof | MILLENNIUM SPECIALTY CHEMICALS, INC. (US) | 2009-07-14 | — | — | US | claimed |
| US-20070238629-A1 | Fragrance compositions from tertiary terpene alcohols | RENESSENZ LLC | 2007-10-11 | — | — | US | claimed |
| WO-2017064628-A1 | C-3 NOVEL TRITERPENONE WITH C-28 UREA DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-04-20 | — | — | WO | disclosed |
| EP-2066648-B1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2017-04-12 | — | — | EP | disclosed |
| US-7560598-B2 | reacting a saturated, tertiary terpene alcohol with hypochloric acid under conditions effective to produce at least one oxidation product selected from the group consisting of cyclic ethers, chloroketones, and mixtures thereof | MILLENNIUM SPECIALTY CHEMICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560598-B2 | reacting a saturated, tertiary terpene alcohol with hypochloric acid under conditions effective to produce at least one oxidation product selected from the group consisting of cyclic ethers, chloroketones, and mixtures thereof | MILLENNIUM SPECIALTY CHEMICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560598-B2 | reacting a saturated, tertiary terpene alcohol with hypochloric acid under conditions effective to produce at least one oxidation product selected from the group consisting of cyclic ethers, chloroketones, and mixtures thereof | MILLENNIUM SPECIALTY CHEMICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070238629-A1 | Fragrance compositions from tertiary terpene alcohols | RENESSENZ LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238629-A1 | Fragrance compositions from tertiary terpene alcohols | RENESSENZ LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238629-A1 | Fragrance compositions from tertiary terpene alcohols | RENESSENZ LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | CD81 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.